Outcome measurement in scleroderma clinical trials

Area of Science:

• Rheumatology
• Clinical Trial Methodology
• Scleroderma Research

Background:

• Scleroderma clinical trials frequently utilize various outcome measures.
• Assessing the clinimetric properties of these measures is essential for reliable results.
• Many existing measures lack the sensitivity to detect therapeutic differences.

Purpose of the Study:

• To review and assess the clinimetric properties of commonly used outcome measures in scleroderma clinical trials.
• To identify limitations in current outcome measures that hinder the detection of drug efficacy.
• To provide recommendations for improving outcome measures in future scleroderma research.

Main Methods:

• Systematic review of 27 controlled intervention studies in the English literature on scleroderma.
• Analysis of outcome measures used, including skin involvement, functional status, physical performance, and internal organ function.
• Evaluation of the ability of measures to detect between- and within-group differences.

Main Results:

• Only nine of 27 studies demonstrated effective therapy.
• Few outcome measures detected significant differences, even with active drugs versus placebo.
• Skin measures showed differences in seven studies; global assessments in three to four.
• Internal organ and physical performance measures rarely detected differences; functional assessments showed limited efficacy detection.

Conclusions:

• Current outcome measures in scleroderma trials often lack the sensitivity to demonstrate drug efficacy.
• There is a need for better, validated, and standardized outcome measures in scleroderma research.
• Future trials require consensus on outcome selection based on reliability, validity, and sensitivity to change.